Roche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
The new VENTANA CLDN18 ( 43-14A ) RxDx Assay helps fulfil an unmet medical need by enabling clinicians to identify patients with gastric or
Oct 28, 2024